The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery.
about
Future technology insight: mass spectrometry imaging as a tool in drug research and development.Influence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerveUse and implications of the harmonic mean model on mixtures for basic research and drug discovery.Guidelines for the welfare and use of animals in cancer research.Pharmacokinetic/ pharmacodynamic-driven drug developmentToward sensitive and accurate analysis of antibody biotherapeutics by liquid chromatography coupled with mass spectrometry.Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity.Sample reduction strategies in discovery bioanalysis.Combined use of in vitro phototoxic assessments and cassette dosing pharmacokinetic study for phototoxicity characterization of fluoroquinolones.Screening candidate anticancer drugs for brain tumor chemotherapy: pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues.Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.Brain mitochondrial drug delivery: influence of drug physicochemical properties.Use of a novel rapid and resource-efficient cassette dosing approach to determine the pharmacokinetics and CNS distribution of small molecule 7-transmembrane receptor allosteric modulators in rat.Synthesis and characterization of a series of chiral alkoxymethyl morpholine analogs as dopamine receptor 4 (D4R) antagonistsSimultaneous analysis of multiple monoclonal antibody biotherapeutics by LC-MS/MS method in rat plasma following cassette-dosing.Development of novel in silico model to predict corneal permeability for congeneric drugs: a QSPR approach.Discovery and Pharmacological Characterisation of a Novel Series of Highly Selective Inhibitors of Cyclin-Dependent Kinases 4 and 6 as Anticancer Agents.Discovery and Characterization of 1H-Pyrazol-5-yl-2-phenylacetamides as Novel, Non-Urea-Containing GIRK1/2 Potassium Channel Activators.Systematic approach to optimize a pretreatment method for ultrasensitive liquid chromatography with tandem mass spectrometry analysis of multiple target compounds in biological samples.
P2860
Q28087460-992659C5-4E43-48AB-91E5-D52AE1500B0FQ33714957-9A0CDFBD-3665-48B6-9621-B95D6B87BDBAQ33843602-4DC65469-70CE-4C8A-A600-F81BF40C19D6Q33903753-A847CB22-699E-4F91-A11B-0E1813870814Q34051505-F7C269BF-5159-42AC-AC22-EA2A22DD34A1Q34359998-BA4B8496-BB58-4EAE-9A28-D8A0B01596C9Q37688607-EF80B30B-D1D6-4BEA-AA6C-AD7FBA4FCE4FQ38118994-D31F3BAA-5055-4E47-B60F-53544613B34BQ38254554-D4AFE4AA-832F-484A-A306-723E09C92771Q39387222-C9E759DC-7AAE-4CA5-805B-40312F43FB52Q39731457-3FF57D5A-5D21-4F6B-97D5-150C0CB2DFB3Q41015003-BB07923F-5204-4BC8-96A8-0EED646A32D8Q41692430-C111DB82-1D7E-4084-999D-2F271AFC3CDDQ41905966-713A8E1F-FF36-4DD8-8EF0-0C7C62E78BD6Q41910990-FFE5E9B3-6B1F-4611-A34D-F429DA7AE5C2Q42624533-16A60E8D-A5B3-4213-BE64-BA3D77034326Q47963513-9B762360-0771-4868-869E-FC91A3891E00Q48143981-54A5C71F-6876-4142-8891-6A6ECEA70721Q53073037-322E3FE0-1BC2-49CC-8296-372DC3691795
P2860
The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The application of cassette do ...... olecule cancer drug discovery.
@ast
The application of cassette do ...... olecule cancer drug discovery.
@en
type
label
The application of cassette do ...... olecule cancer drug discovery.
@ast
The application of cassette do ...... olecule cancer drug discovery.
@en
prefLabel
The application of cassette do ...... olecule cancer drug discovery.
@ast
The application of cassette do ...... olecule cancer drug discovery.
@en
P1476
The application of cassette do ...... olecule cancer drug discovery.
@en
P2093
Florence I Raynaud
Nicola F Smith
P304
P356
10.1158/1535-7163.MCT-06-0324
P50
P577
2007-02-01T00:00:00Z